Prostate cancer Posts on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Posted by on Jul 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients. Some background Localized prostate cancer...

Read More

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

Posted by on Jul 17, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide. Some background...

Read More

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...

Read More

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality. Some background Prostate cancer is often treated with radiation therapy to...

Read More

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Evaluating the association between the lowest PSA value after prostate surgery and the occurrence of biochemical recurrence in patients with localized prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the association between the lowest PSA value after radical prostatectomy (RP; surgery to remove the prostate) and the occurrence of biochemical recurrence (BCR) in patients with localized prostate cancer (PCa). The study found that a higher PSA value after RP and a shorter time to reach this...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients.   Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Read More

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Posted by on Jun 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...

Read More

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Posted by on Jun 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP. Some background Localized prostate cancer (PCa)...

Read More

Long-term outcomes of focal cryotherapy in low- to intermediate-risk prostate cancer.

Long-term outcomes of focal cryotherapy in low- to intermediate-risk prostate cancer.

Posted by on Jun 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study looked at the use of focal cryotherapy (FC) for the treatment of low- to intermediate-risk prostate cancer (PC). The authors found that the use of FC was safe and increased time to further therapy with similar survival compared to active surveillance (AS).  Some background PC is one of the most common forms of...

Read More

Analyzing the effectiveness and safety of Lutetium-177–labeled PSMA–targeted therapy in patients with metastatic castration-resistant prostate cancer.

Analyzing the effectiveness and safety of Lutetium-177–labeled PSMA–targeted therapy in patients with metastatic castration-resistant prostate cancer.

Posted by on May 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects. Some...

Read More